Project Grant R37CA297078
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $640K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded April 1, 2026, with completion scheduled for March 31, 2028. The award supports research investigating dual-targeting therapeutic strategies for acute myeloid leukemia (AML) by combining BCL-2 inhibition with CD123-directed natural killer (NK) cell engager immunotherapy. The research will evaluate the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $399,829 to the University of Maryland, Baltimore on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) for research addressing drug resistance in acute leukemias. The project, titled "Protein Degradation Strategies to Overcome Menin Drug Resistance in Acute Leukemias," will be completed by April 30, 2028. The research focuses on developing proteolysis-targeting chimera...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 11, 2025 through August 31, 2030. The project, "Targeting Polyamine Metabolism in Relapsed Acute Myeloid Leukemia Stem Cells," focuses on fundamental research to understand and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs). The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...
- This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
- This $878,400 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research characterizing vitamin B6 pathway dependency in acute myeloid leukemia (AML) at Cold Spring Harbor Laboratory from January 2023 through December 2027. The research aims to further the understanding of the underlying mechanisms of AML by studying abnormal vitamin pathways and metabolic programming...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $885,632 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct research on interrogating erythroid differentiation and the BCL-XL axis in TP53-mutated acute myeloid leukemia (AML). The award, effective April 2, 2026, through March 31, 2028, supports fundamental and applied laboratory research aimed at developing novel therapeutic approaches to overcome...